Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Molecular profile Clear all
Completed Phase 2 Interventional

Molecular Marker Profiling of Axillary Lymph Nodes in Predicting Response in Patients With Locally Advanced or Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery

NCT00233974
View directory record Official record
Conditions
Breast Cancer
Interventions
PET (positron emission tomography)
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Oct 21, 2026, 6:36 PM EDT
Not listed No phase listed Observational

Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients

NCT06090513
View directory record Official record
Conditions
Advanced Cancer, Solid Tumor, Adult, Myeloid Malignancy
Interventions
Comprehensive Genomic Profile testing; ELIA software; Molecular Genetic Pathologist consultation, limited genetic testing or no testing
Combination Product · Diagnostic Test
Lead sponsor
Bien-Willner Physicians Group PA
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 21, 2026, 6:36 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

NCT00720304
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
docetaxel, erlotinib hydrochloride, fluorescence in situ hybridization, polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, therapeutic conventional surgery, intensity-modulated radiation therapy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 21, 2026, 6:36 PM EDT
Not yet recruiting No phase listed Observational

Methadone Dose Monitoring With a Remote Medication Monitor

NCT06837571
View directory record Official record
Conditions
Methadone Toxicity, Methadone Overdose, Pain, Chronic, Drug Metabolism, Poor, CYP2D6-Related, Metabolism Medication Toxicity
Interventions
Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo, Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo, ISF Extraction Device 2
Diagnostic Test · Drug · Device
Lead sponsor
Cari Health Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Lemon Grove, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 21, 2026, 6:36 PM EDT
Completed Phase 2 Interventional Results available

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

NCT01858389
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Dacomitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Beverly Hills, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 21, 2026, 6:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Genetic Basis For Variation In NSAID Analgesia In A Clinical Model Of Acute Pain

NCT00115752
View directory record Official record
Conditions
Pain
Interventions
Valdecoxib, COX Inhibitor
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
7 Years to 35 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 6:36 PM EDT
Completed No phase listed Observational

Study of Molecular Profile-Related Evidence to Determine Individualized Therapy for Advanced or Poor Prognosis Cancers

NCT02534675
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
La Jolla, California • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 21, 2026, 6:36 PM EDT
Recruiting Phase 2 Interventional

Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle

NCT07453069
View directory record Official record
Conditions
Vaginal Dysbiosis
Interventions
FB-301, Placebo, Chlorhexidine (0.5%) Vaginal Cleanse, Sham vaginal cleanse (saline)
Drug · Other
Lead sponsor
Freya Biosciences ApS
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Wichita, Kansas • Waltham, Massachusetts • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 6:36 PM EDT
Recruiting Phase 3 Interventional

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

NCT05848713
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 6:36 PM EDT
Withdrawn Not applicable Interventional

iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

NCT03446638
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction, Low-dose cytarabine, Supportive care alone, Computational biology simulations software
Drug · Other · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 21, 2026, 6:36 PM EDT
Withdrawn No phase listed Observational

Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide

NCT02250404
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 21, 2026, 6:36 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)

NCT04861103
View directory record Official record
Conditions
Pregnancy, High Risk, Anticoagulants
Interventions
Lovenox
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 21, 2026, 6:36 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis

NCT00117377
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
20 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
3
States / cities
New York, New York • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2007 · Synced Oct 21, 2026, 6:36 PM EDT
Completed Phase 1 Interventional

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

NCT03552718
View directory record Official record
Conditions
Colorectal Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Pancreatic Cancer, Liver Cancer
Interventions
YE-NEO-001
Biological
Lead sponsor
NantBioScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 21, 2026, 6:36 PM EDT
Completed Not applicable Interventional

Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma

NCT03739372
View directory record Official record
Conditions
Glioma, Glioma of Brain, Cancer, Pediatric Cancer, Pediatric Brain Tumor, Astrocytoma, Glioblastoma, Hemispheric
Interventions
Specialized tumor board recommendation
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 21 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 6:36 PM EDT
Completed No phase listed Observational

Genomic Profiling Assay in Phase I

NCT02437617
View directory record Official record
Conditions
Advanced Cancers
Interventions
Tumor Tissue
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 21, 2026, 6:36 PM EDT
Completed Early Phase 1 Interventional Results available

Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca

NCT01074814
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Approved therapy will be assigned based on molecular profile and RPMA results
Drug
Lead sponsor
Translational Drug Development
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Fairfax, Virginia • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 21, 2026, 6:36 PM EDT
Withdrawn Phase 2 Interventional

Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer

NCT02967770
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Molecularly Tailored Second Line Therapy, Standard of Care Second Line Therapy
Other · Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 21, 2026, 6:36 PM EDT
Not listed No phase listed Observational

Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients

NCT02160366
View directory record Official record
Conditions
Advanced Cancers
Interventions
Biomarker Research
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 21, 2026, 6:36 PM EDT
Not yet recruiting Phase 2 Interventional

Real-world Trial of Individualized Precision Oncology

NCT07346209
View directory record Official record
Conditions
Metastatic Cancer, Unresectable Carcinoma
Interventions
Molecularly matched therapy, Standard of care
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 6:36 PM EDT
Terminated Not applicable Interventional Results available

Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach

NCT02358863
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Modified FOLFOX6, Docetaxel/Capecitabine, Cisplatin/Irinotecan, Cisplatin/Docetaxel, IRI/EPI, EPI/Docetaxel, Irinotecan/Docetaxel, Docetaxel
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 21, 2026, 6:36 PM EDT
Terminated Phase 1 Interventional

Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot

NCT01007695
View directory record Official record
Conditions
Cancer
Interventions
Valproic Acid
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 21, 2026, 6:36 PM EDT
Recruiting Phase 1 Interventional

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

NCT06218303
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
MUC1 Peptide Vaccine, Hiltonol®, Aromatase Inhibitor, Selective estrogen receptor modulator (SERM)
Biological · Drug
Lead sponsor
Finn, Olivera, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 6:36 PM EDT
Not listed No phase listed Observational

PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)

NCT06390709
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lab Collection Only
Other
Lead sponsor
Scipher Medicine
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Whittier, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 21, 2026, 6:36 PM EDT